An implant having a size of a matchstick can revolutionize HIV prevention regimes. The early trials have suggested that the device can stop people at risk by contracting the virus for almost one year at a time.
The device utilizes a molecule called MK-8591 that is about ten times more effective as an HIV inhibitor than the medicines that are currently available in the market. Furthermore, it boasts off a very strong barrier against resistance.
It gradually let goes of the drug and then maintains a highly consistent level of it in one’s body and taking this prophylactically can actually save you from getting infected.
At present,, individuals that are at a high risk of contracting HIV must take one pill on daily basis in order to ensure their protection.
An implant, or a monthly pill that contains the same active ingredient might be a better option for those communities who are at a very high risk.
The President of the International AIDS Society, Anton Pozniak said that the implant further offers a different choice for people who, in the future, might also have the availability of pills and injectables for preventing the infection.
The Phase 2 of the trial took place in Rwanda, Kenya, and the US among the healthy, low-risk, and HIV negative people. The initial results depicted that the vaccines were being well-tolerated among the subjects.
A Phase 3 of the trial is currently in planning.
Director of the Global HIV Vaccine Enterprise, Roger Tatoud said that these are very promising times in the research of HIV vaccine having several efficacy clinical trials going on, new developmental approaches, and also a growing sense of getting closer to the goal that is an effective vaccine.